Kleo is developing two types of small molecules to treat cancer, infectious diseases, and a broad range of indications: Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). We believe our technology represents a breakthrough in safer, more efficacious, and more convenient treatment options.
Kleo was founded in 2015 by Dr. David A. Spiegel, Yale University Professor of Chemistry and Pharmacology. The company is based in New Haven, CT.
Founders: David A. Spiegel and Roy Prieb